To provide pharmacists with up-to-date information regarding their role in the diagnosis and treatment of patients with head and neck cancer.
This activity is designed for pharmacists. No prerequisites required.
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CE activity. At the conclusion of this activity, the participant should be able to:
- Examine the epidemiology and pathology of head and neck cancer (HNCA), including the growing understanding of the molecular biology of the disease.
- Discuss the multimodal approach to HNCA treatment, including the roles of surgery, radiation therapy, and chemotherapy.
- Describe emerging strategies in HNCA therapy, including the potential role of antibody therapy.
- Establish the role of the hospital pharmacist as a key member of a multidisciplinary treatment team.
The University of Tennessee College of Pharmacy (UTCOP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) to provide continuing education for pharmacists.
CREDIT DESIGNATION STATEMENT
This program is approved for 2 hours of credit (0.2 CEUs) and is sponsored by the University of Tennessee College of Pharmacy, which is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Program #064-000-05-260-H01. This continuing education activity was produced under the supervision of Glen E. Farr, PharmD, Associate Dean of Continuing Pharmacy Education, University of Tennessee College of Pharmacy.
The estimated time to complete this educational activity: 2 hours.
Release date: April 15, 2006.
Expiration date: April 15, 2008.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of a program sponsored or co-sponsored by the UTCOP may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.
This program is supported by an educational grant from Bristol-Myers Squibb and ImClone.